Black Diamond TherapeuticsBDTX
BDTX
About: Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Employees: 54
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
7% more funds holding
Funds holding: 89 [Q2] → 95 (+6) [Q3]
2.89% more ownership
Funds ownership: 83.09% [Q2] → 85.99% (+2.89%) [Q3]
3% less capital invested
Capital invested by funds: $218M [Q2] → $211M (-$6.47M) [Q3]
27% less call options, than puts
Call options by funds: $7.05M | Put options by funds: $9.67M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11
364%
upside
Avg. target
$11
364%
upside
High target
$11
364%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 37 / 160 met price target | 364%upside $11 | Buy Reiterated | 6 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
3 weeks ago
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts
Black Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables targeting entire families of oncogenic mutations, offering potential solutions for underserved cancer populations like non-classical NSCLC and glioblastoma. BDTX's $112.7 million cash reserves will support operations through Q2 2026. Restructuring efforts will prioritize high-value programs like BDTX-1535.
Positive
Zacks Investment Research
1 month ago
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
2 months ago
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
2 months ago
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
Neutral
Seeking Alpha
3 months ago
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic.
Neutral
GlobeNewsWire
3 months ago
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the Company's expected cash runway into Q2 2026.
Neutral
GlobeNewsWire
3 months ago
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed
Neutral
GlobeNewsWire
4 months ago
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass.
Neutral
GlobeNewsWire
4 months ago
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health
Positive
Zacks Investment Research
5 months ago
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charts implemented using Lightweight Charts™